Relmada Therapeutics Investor Presentation — March 2022

Document content

Targeting MajorAdvances in Treatmentof CNS DisordersMarch 7, 2022 I Nasdaq: RLMD

1DisclosuresCertain statements contained in this presentation or in other documents of RelmadaTherapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward-looking statements.” These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate,” “projected” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. These statements are based upon thecurrent beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Statements regarding future action, future performance and/or future results, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or approval and commercial launch and sales results (if any) of the Company’s formulations and products and regulatory filings related to the same may differ from those set forth in the forward-looking statements. Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all, or that such market size estimates will prove accurate.Because actual results are affected by these and other potential risks, contingencies and uncertainties, the Company cautionsinvestors that actual results may differ materially from those expressed or implied in any forward-looking statement. It is not possible to predict or identify all such risks, contingencies and uncertainties. The Company identifies some of these factors in its Securities and Exchange Commission (“SEC”) filings on Forms 10-K, 10-Q and 8-K, and investors are advised to consult the Company’s filings for a more complete listing of risk factors, contingencies and uncertainties affecting the Company and its business and financial performance.The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised to consultfurther disclosures that the Company makes or has made on related subjects in the Company’s Form 10-K, 10-Q and 8-K reports.2Investment Highlights

Highly CompellingOpportunity in REL-1017

Multiple Catalysts Expected Over Next 18 Months

CNS Focus with Lead Program in Major Depressive Disorder (MDD)

CNS= Central Nervous System**Our fiscal year end is December 31. The periods referred to in this slide are calendar years and quarters. 3Major Depressive Disorder & REL-1017Prevalence of Depression